Drug Targeting at Bend Research

Many therapeutically active molecules suffer from mechanism-based or off-target toxicities. An estimated 30% of clinical attrition is due to candidate toxicity or other safety issues, representing lost economic and therapeutic opportunity measured in millions or billions of dollars. Selective delivery of drugs and drug candidates to targeted cells or tissues has the potential to expand the therapeutic window and enable development of novel drugs for new and existing therapeutic targets. Bend Research has addressed this need using a drug-targeting approach based on detailed predictive modeling and the development of patented materials for use in targeted formulations.

Topics: 
Bioavailability Enhancement